/** Title: Windlas Biotech Q1 FY27: Record Revenue, CDMO Strength, and a Plant 6 Milestone Ahead Slug: windlas-q1fy27 Cover Image Description: An ultra-realistic corporate finance scene showing a clean desk with a laptop displaying three minimalist charts: a rising quarterly revenue line ending at 248, a segmented bar showing revenue mix dominated by CDMO with smaller blocks for exports and trade generics, and a capacity utilization gauge around 66 percent with a highlighted upcoming capacity block representing Plant 6 commissioning in H1. Neutral office lighting, professional dashboard aesthetic, no logos or text labels. Short Title: Windlas record quarter and Plant 6 */

Windlas Biotech Q1 FY27: Record Revenue, CDMO Strength, and a Plant 6 Milestone Ahead

Windlas Biotech opened FY27 with another quarter of growth, extending a long streak of consistent execution. In Q1 FY27, the company reported its highest ever quarterly revenue of INR 248 crore, up 18 percent year on year. Adjusted for the non-cash ESOP charge of about INR 7.2 crore, EBITDA rose 26 percent year on year to INR 34 crore, and adjusted PAT increased 37 percent to INR 25 crore. On a reported basis including ESOP expense, EBITDA was INR 27 crore and PAT was INR 18 crore.

Management positioned the quarter as a continuation of the company’s broader trajectory rather than a one-off spike. The call repeatedly emphasized that quarterly movements at the vertical level can be noisy, and that company-level performance is the better lens. That message matters in Q1 FY27 because Windlas delivered strong growth in its largest vertical while one segment faced a policy-driven disruption.

CDMO led growth while Trade Generics stayed in reset mode

Windlas operates through three business verticals. The Generic Formulations CDMO business remains the core, supplying branded generic products to pharmaceutical companies that sell under their own brands. In Q1 FY27, CDMO revenue rose to INR 207 crore from INR 160 crore in Q1 FY26, a 29 percent increase. Management attributed the outcome to continued conversion of business development efforts into revenue, deeper engagement with customers, and the growing participation of newer capabilities such as injectables and the Plant 2 extension.

Trade Generics and Institutional revenue was INR 30 crore in Q1 FY27 compared with INR 44 crore in Q1 FY26, a decline of 32 percent. Management linked the drop to the discontinuation of codeine-based products. In the call, leadership acknowledged that the momentum in this vertical has taken a hit and described it as temporary for a few quarters rather than a long-term structural impairment. The company’s focus is on portfolio expansion through new launches, geographic expansion into new states, deeper penetration in existing territories, and strengthening institutional account additions. Management also highlighted work to shift liquid capacity towards other products and pack-size variants to better utilize existing lines.

Exports remained a small base but showed sharp growth. Q1 FY27 exports revenue increased to INR 11 crore from INR 6 crore in Q1 FY26, a 79 percent rise. Management reiterated that exports is a longer gestation business with dossier registrations, audits, and geography expansion leading revenue by multiple quarters. They indicated continued work on registrations, geographies, and plant approvals, without disclosing specific target markets due to competitive sensitivity.

Margin quality and what the ESOP adjustment changes

One reason the quarter reads differently depending on the chosen metric is the ESOP charge. Windlas presented both adjusted and reported profitability and also shared a forward schedule of ESOP P and L impact by half-year. In Q1 FY27, the ESOP expense was about INR 7.16 crore to INR 7.2 crore, and management reiterated that it is non-cash and does not affect operating cash flows.

On the operating line, gross margin in Q1 FY27 was 38.4 percent, broadly stable versus 38.3 percent in Q1 FY26. Management attributed the margin profile to business mix, operational efficiencies, and the product portfolio conversion within CDMO, alongside higher export contribution. They also acknowledged that the fall in Trade Generics and Institutional, which is typically higher gross margin, created a mix headwind that was offset this quarter by CDMO portfolio and efficiencies.

The company also discussed the environment for APIs and inputs. Management described continued volatility in pricing and availability, linked partly to geopolitical uncertainty. During the quarter, Windlas carried higher inventory and saw some increase in receivables during the period, although management said working capital was brought back to similar levels by the end.

Plant 6 is the next operational milestone

The most important near-term milestone is Plant 6, an oral solids facility meant to expand core capacity. Management stated mechanical completion is done, validations and customer audits are in progress, and commercialization is targeted by the end of H1 FY27, effectively end of Q2 with minor timing variation.

On the call, management explained why Plant 6 should ramp more smoothly than injectables did. Injectables represented a new dosage form expansion, which typically requires a learning curve for both the company and customers. Plant 6 is positioned as an expansion of the core oral solids platform, allowing Windlas to offer existing portfolios from a new plant once customer approvals are obtained.

Management also discussed how to interpret capacity and revenue potential. They mentioned that with Plant 6, the company can deliver around INR 1,100 crore of revenue. They added that internal efficiency initiatives have historically increased the achievable output by 10 to 15 percent beyond initial estimates. They also confirmed that they see additional upside of roughly INR 100 to INR 150 crore beyond the initial figure through debottlenecking and efficiency.

Plant 6 will also raise depreciation. Management indicated quarterly depreciation could increase by around INR 3 crore per quarter after commercialization, with partial impact in Q2 and fuller impact in Q3.

Capital allocation and balance sheet stance

Alongside operating execution, Windlas highlighted capital allocation actions that directly benefit shareholders. The company completed a share buyback of about INR 47 crore through a tender offer at INR 1,000 per share, with no promoter participation. It also paid a FY26 dividend of INR 13 crore, equal to INR 6.30 per share. The presentation stated that the company aims to keep dividend payout near 20 percent of consolidated PAT, subject to capital needs and cash flow.

The longer-term financial charts in the presentation show steady expansion. FY26 revenue was INR 904 crore, with EBITDA and PAT of INR 105 crore and INR 66 crore on a reported basis. The company also emphasized its liquidity position and reported being net debt free with strong net liquidity as of FY26, and an ICRA rating of A plus stable.

What to watch next

The Q1 FY27 setup leaves investors with three operational checkpoints. First is Plant 6 commissioning and the pace of customer approvals and volume conversion through H2 FY27. Second is the continued trajectory of injectables, where management stated the business is back on track and a potential capacity addition could be executed in about 6 to 8 months once decided. Third is the recovery path for Trade Generics and Institutional after codeine discontinuation, where management’s action plan is clear but quarterly timing remains uncertain.

Windlas ended the quarter with a familiar message: execution discipline matters more than chasing short-term signals. In Q1 FY27, the company backed that message with record revenue, stronger adjusted margins, and a time-bound operational milestone that can shape the next leg of growth.